GlassScriptPhysician profile
Dorothy Tseng Yip
NPI 1558654301
$5,854.89
in general payments reported to CMS, 2019-2025
34 companies · $2,945 in 2025
The $2,945 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $704 · 2023: $34.01 · 2024: $1,934 · 2025: $2,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,913.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,173.85 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $539.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $470.02 | 2021-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $381.55 | 2024-2025 | Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $342.32 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $334.22 | 2024-2025 | Hyqvia, Cuvitru, Takhzyro |
| Ars Pharmaceuticals Operations, INC. | $313.53 | 2025 | Neffy |
| Csl Behring | $267.97 | 2024-2025 | Hizentra, Haegarda, Andembry |
| Pharming Healthcare, INC. | $253.97 | 2024-2025 | Ruconest |
| Galderma Laboratories, L.P. | $184.53 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $173.45 | 2024 | Ayvakit |
| Aerin Medical INC. | $145.04 | 2022 | |
| Ionis Pharmaceuticals, INC. | $140.60 | 2025 | Dawnzera |
| Novartis Pharmaceuticals Corporation | $136.75 | 2024-2025 | |
| Heron Therapeutics, INC. | $121.91 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $116.29 | 2024 | Auvi-Q |
| Genentech USA, INC. | $114.86 | 2024-2025 | Xolair |
| Grifols USA, LLC | $91.71 | 2025 | Xembify |
| E.R. Squibb & Sons, L.L.C. | $75.80 | 2022 | |
| Abbvie INC. | $62.72 | 2023-2024 | |
| Octapharma USA, INC. | $59.18 | 2024 | Octagam Immune Globulin (Human), Cutaquig |
| Biocryst US Sales Co., LLC | $58.04 | 2025 | Orladeyo |
| Optinose US, INC. | $54.84 | 2021-2024 | |
| 180 Medical, INC. | $51.81 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.39 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.26 | 2022 | |
| Alk-Abello, INC | $17.87 | 2025 | Grastek, Odactra, Ragwitek |
| Merck Sharp & Dohme LLC | $17.61 | 2022 | |
| Cycle Pharmaceuticals INC | $17.21 | 2024 | Sajazir |
| Incyte Corporation | $17.19 | 2024 | Opzelura |
| Sanofi-Aventis U.S. LLC | $14.79 | 2022 | |
| Phadia US INC. | $13.38 | 2024 | Immunocap |
| Lilly USA, LLC | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Yip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.